Table 1.

Patient Characteristics

No. of patients	120
Year of surgery	1999–2017
Before 2010	30	25.0%
2010–2012	33	27.5%
2013–2014	34	28.3%
2015–2017	23	19.2%
Sex
Male	72	60.0%
Female	48	40.0%
Median age, y (IQR)	45 (18–78)
Symptoms at onset
Seizures	74	60.7%
Focal seizures with secondary generalization	53	71.6%
Focal seizures with maintained awareness	17	23.0%
Focal seizures with impaired awareness	4	5.4%
Focal neurological symptoms	25	20.5%
Headache/intracranial hypertension	19	15.6%
Cognitive impairment/behavioral changes	8	6.5%
Dizziness/gait disturbances	7	5.7%
None	5	4.1%
Contrast enhancement
No	83	73.5%
Yes	30	26.5%
Main tumor location
Temporal	52	43.3%
Frontal	42	35.0%
Parietal	16	13.3%
Insula	8	6.7%
Occipital	2	1.7%
Tumor extension
1 lobe	79	65.9%
≥ 2 lobes	23	19.1%
1 or > 1 lobes with involvement of deep structures (either corpus callosum, basal ganglia or brainstem)	18	15.0%
Molecular data
pTERT mutation
pTERT-mutant	30	50.8%
pTERT-intact	29	49.2%
EGFR amplification
EGFR-amplified	9	14.0%
EGFR-intact	54	86.0%
pMGMT methylation
pMGMT-methylated	31	40.0%
pMGMT-unmethylated	46	60.0%
pTERT-mutant and EGFR-amplified	1	2.0%
Extent of resection (EOR)
Non-gross total resection (non-GTR)	83	69.2%
Gross total resection (GTR)	37	30.8%
Postoperative KPS
80–100	120	100.0%
Postoperative management
Observation with MRI	57	47.5%
Radiotherapy or radio-chemotherapy	37	30.8%
Upfront chemotherapy alone	26	21.7%
Disease progression
Yes	78	65.0%
No	31	25.8%
Patients’ status
Dead	81	67.5%
Alive	33	27.5%
Lost to follow-up	6	5.0%

IQR: interquartile range; KPS: Karnofsky Performance Status.